Intangible Assets

6 Months Ended

Jun. 30, 2013

Intangible Assets [Abstract]

INTANGIBLE ASSETS

NOTE D — INTANGIBLE ASSETS

Intangible assets as of June 30, 2013 and December 31, 2012 consisted of the following (in thousands):

	Weighted Average Amortization Period	June 30, 2013
		COST		Accumulated Amortization		Net
Support Vector Machine (SVM) technology	108 months	$	500	$	84	$	416
Laboratory developed test (LDT) technology	164 months	$	1,482	$	134	$	1,348
Flow Cytometry and Cytogenetics technology	202 months	$	1,000	$	75	$	925
Total		$	2,982	$	293	$	2,689

	Weighted Average Amortization Period	December 31, 2012
		COST		Accumulated Amortization		Net
Support Vector Machine (SVM) technology	108 months	$	500	$	56	$	444
Laboratory developed test (LDT) technology	164 months	$	1,482	$	81	$	1,401
Flow Cytometry and Cytogenetics technology	202 months	$	1,000	$	45	$	955
Total		$	2,982	$	182	$	2,800

We recorded approximately $55,000 and $56,000 in straight-line amortization expense of intangibles for the three months ended June 30, 2013 and 2012, respectively, and approximately $111,000 and $70,000 in straight-line amortization expense of intangibles for the six months ended June 30, 2013 and 2012, respectively, as research and development expenses in the consolidated statement of operations. We will record all amortization of intangibles in that category until the time that we have products, services or cost savings directly attributable to these intangible assets that would require that it be recorded in cost of goods sold.

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2013 is as follows (in thousands):

Year Ending December 31,
Remainder of 2013	$	112
2014		223
2015		223
2016		223
2017		223
2018		223
Thereafter		1,462
Total	$	2,689